Kacper Pempel | REUTERS
A regulatory probe in the United Kingdom into NortonLifeLock's $8.6 billion deal with Avast and higher inflation costs are casting uncertainty over the company's stock, according to Morgan Stanley.
A regulatory probe in the United Kingdom into NortonLifeLock's $8.6 billion deal with Avast and higher inflation costs are casting uncertainty over the company's stock, according to Morgan Stanley.